Business Context and Reporting Period
Envoy Medical, Inc. (formerly Anzu Special Acquisition Corp I) filed a Form 8-K on December 20, 2024. The filing reports the entry into a Material Definitive Agreement with Anzu SPAC GP I LLC ("Anzu"), the company's former sponsor, following a business combination completed on September 29, 2023.
Key Financial Metrics and Transaction Details
This filing does not report standard operating financial metrics such as revenue, profit, cash flow, or liquidity. Instead, it details a specific capital structure transaction involving the following figures:
- Accrued Dividends Waived: $3,733,333 (12% annual rate on Series A Preferred Stock).
- Preferred Stock Held by Anzu: 2,500,000 shares.
- Restricted Common Stock Held by Anzu: 1,000,000 shares (previously subject to vesting).
- Shares Converted: 373,333 shares of Preferred Stock converted into 1,028,986 shares of Class A Common Stock.
- Conversion Price Adjustment: Temporary reduction from $11.50 to $3.63 per share for the period of December 20, 2024, through January 20, 2025.
Material Changes Versus Prior Period
The filing outlines significant changes to the rights of security holders and the company's capital obligations effective December 20, 2024:
- Debt Obligation Reduction: The company's obligation to pay $3,733,333 in accrued dividends to Anzu was waived.
- Share Liquidity: 1,000,000 previously restricted shares held by Anzu were released from vesting requirements and became freely tradable.
- Capital Structure: A portion of the Preferred Stock was converted into Common Stock at a significantly reduced temporary conversion price.
Guidance, Outlook, and Risks
The filing does not provide forward-looking guidance, management commentary on operational outlook, or specific risk factors beyond the transaction details. The primary contingency noted is the temporary nature of the conversion price reduction, which is set to expire on January 20, 2025. The filing incorporates the full terms of the Conversion and Waiver Agreement by reference.
Key Facts for Investor Verification
- Verify the impact of the 1,028,986 newly issued shares on total share count and potential dilution.
- Confirm the expiration of the temporary conversion price reduction on January 20, 2025, and the reversion to the standard $11.50 price.
- Review the full text of the Conversion and Waiver Agreement (Exhibit 10.1) for any additional covenants or conditions not summarized in the 8-K.
- Assess the financial benefit of the $3.73 million dividend waiver on the company's cash flow position.